Abstract:Jinxian Xu, Yang Zhang, Lujian Zhu, Shiyue Tang, Hanglu Xu, Dehe Zhang, Haijun Chen, Jing Zhou Department of Infectious Diseases, Zhejiang University Medical College Affiliated Jinhua Hospital, Jinhua, People's Republic of China Correspondence: Jing Zhou, Department of Infectious Diseases, Zhejiang University Medical College Affiliated Jinhua Hospital, Jinhua, People's Republic of China, Email Background: Chronic hepatitis B (CHB) presents a global health challenge due to its potential to cause severe liver conditions such as hepatocellular carcinoma (HCC) and cirrhosis. Prior research has established a correlation between CHB infection with low-level viremia (LLV) and liver disease progression, such as increased HCC incidence. This study aims to investigate whether LLV during treatment with nucleos(t)ide analogs (NAs) contributes to the accelerated progression of liver fibrosis (LF). Methods: This retrospective cohort study at Jinhua Central Hospital focused on CHB patients undergone NA monotherapy for over 96 weeks. Patients were categorized into maintained virological response (MVR) and LLV groups based on hepatitis B virus (HBV) DNA levels. The study assessed LF using various markers and methods, including chitinase 3-like 1 protein (CHI3L1), aspartate aminotransferase-to-platelet ratio index (APRI), fibrosis-4 (FIB-4) score, and transient elastography. Results: Analysis was conducted on 92 CHB patients, categorized into LLV (n=42) and MVR (n=50) groups, following the exclusion of 101 patients for various reasons. Significant findings included lower baseline HBV DNA in MVR (< 20 IU/mL) compared to LLV (67.8 IU/mL, P< 0.001) and different AST/ALT ratios (LLV: 1.1, MVR: 1.36, P=0.011). LF was assessed using CHI3L1, FIB-4, and APRI, with LLV showing a higher baseline CHI3L1 (LLV:83.3 ng/mL vs MVR: 54.5 ng/mL, P=0.016) and scores compared to MVR, indicative of fibrosis. CHI3L1 levels in LLV were higher at baseline and weeks 48, 72, and 96 than MVR, with significance at baseline (P=0.038) and week 48 (P=0.034). Liver stiffness measurement (LSM) showed a time-dependent decline in both groups but no significant intergroup differences. Conclusion: Non-invasive monitoring of CHB patients who have received treatment indicates that LLV contributes to the progression of LF, necessitating proactive adjustment of antiviral treatment strategies. Keywords: chronic hepatitis B, low-level viremia, liver fibrosis, non-invasive methods, treatment strategies Chronic Hepatitis B (CHB) presents a global health challenge, contributing significantly to global morbidity and mortality rates. 1 The major concern regarding CHB is its potential progression to severe liver conditions such as hepatocellular carcinoma (HCC) and cirrhosis. 2 Nucleic acid testing technology advancements, particularly high-sensitivity hepatitis B virus (HBV)-DNA testing techniques, have achieved a detection limit of 10 IU/mL. 3 This advancement raises the possibility that some patients, previously categorized as having achieved a complete virological response, might be false negatives. Moreover, these technological improvements facilitate the identification of more patients exhibiting low-level viremia (LLV) following treatment with nucleos(t)ide analogs (NAs). 4 Currently, there is no international consensus on defining LLV; definitions vary across different guidelines and among researchers. Both domestic and international treatment guidelines and consensus statements suggest that patients experiencing LLV (< 2000 IU/mL) during monotherapy with tenofovir or entecavir should continue their monotherapy, regardless of alanine aminotransferase (ALT) levels. However, it is important to note that the evidence supporting this recommendation is low. 5–7 Furthermore, there is a lack of comprehensive clinical data to determine whether the occurrence of LLV during CHB monotherapy with entecavir or tenofovir is a benign outcome. Therefore, this study aims to determine if the presence of LLV during treatment with NAs contributes to the accelerated progression of liver fibrosis (LF). It evaluates the impact of persistent LLV on LF by monitoring dynamic changes in fibrosis markers such as serum chitinase 3-like 1 protein (CHI3L1), aspartate aminotransferase-to-platelet ratio index (APRI), and fibrosis-4 (FIB-4), providing evidence-based medical grounds for further diagnostic and treatment strategy adjustments. This retrospective cohort study was conducted with CHB patients treated at Jinhua Central Hospital. A total of 193 patients who received monotherapy with NAs between January 2019 and September 2023 were selected for the study. Eligible patients had undergone NA monotherapy for over 96 weeks, including cases with mainta -Abstract Truncated-

Fatty liver is not independently associated with the rates of complete response to oral antiviral therapy in chronic hepatitis B patients

The co-existence of NAFLD and CHB is associated with suboptimal viral and biochemical response to CHB antiviral therapy: a systematic review and meta-analysis

Adverse Effect of Nonalcoholic Fatty Liver Disease on the Therapeutic Response in Patients with Chronic Hepatitis B

Antiviral therapy response in patients with chronic hepatitis B and fatty liver: A systematic review and meta‐analysis

Association between nonalcoholic fatty liver disease status changes and antiviral efficacy in chronic hepatitis B

Liver biopsy-proven non-alcoholic fatty liver disease predicts no impact on antiviral response in patients with chronic hepatitis B

The Impact of Early Rapid Virological Response on the Outcomes of Hepatitis B Associated Acute on Chronic Liver Failure During Antiviral Treatment

Efficacy of different therapeutic modalities for patients with acute-on-chronic liver failure induced by hepatitis B

Fatty liver is associated with significant liver inflammation but does not increase fibrosis burden in Chronic HBV infection

Fatty liver is associated with significant liver inflammation but does not increase fibrosis burden in Chronic Hepatitis B

Impact of Nonalcoholic Fatty Liver Disease Status Change on Antiviral Efficacy of Nucleos(t)ide Analogues in HBeAg‐positive Chronic Hepatitis B

Fatty liver is associated with significant liver inflammation and increases the burden of advanced fibrosis in chronic HBV infection

Association Between Hepatic Steatosis And Entecavir Treatment Failure In Chinese Patients With Chronic Hepatitis B

Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis

NAFLD is associated with less severe liver fibrosis in chronic hepatitis B: A multi-center, retrospective study

Prevalence of nonalcoholic fatty liver disease in patients with hepatitis B: A meta-analysis

Association of baseline vitamin D level with genetic determinants and virologic response in patients with chronic hepatitis B.

Non-Invasive Monitoring of the Impact of Low-Level Viremia on Liver Fibrosis in Treated Chronic Hepatitis B Patients

Factors predicting outcomes of hepatitis B-related cirrhosis patients with long-term antiviral therapy

Nonalcoholic Fatty Liver Disease is Associated with Lower Hepatitis B Viral Load and Antiviral Response in Pediatric Population

Influence of weight management on the prognosis of steatohepatitis in chronic hepatitis B patients during antiviral treatment